News & Views

  • Merger Integrates Advanced Therapies Expertise

Merger Integrates Advanced Therapies Expertise

Oct 19 2020 Read 326 Times

A strategic CRO merger, which has seen mRNA technologies developer Prolytic successfully integrated into the Kymos Group, has broadened the portfolio offering of services for innovative small and large molecules, generics, biosimilars, antibodies, biomarkers, ADA (anti-drug antibodies), ADC (antibody-drug conjugates), hormones, enzymes and nucleic acids. 
“Today’s market wants full-service providers and one-stop-solutions. With this merger we will be able to think globally and act locally, providing our clients with a reliable, trustworthy and much-improved service,” said Dr. Dorothee Krone, managing director at Prolytic. “Small and mid-sized companies feel comfortable working with us. Kymos can help us cover the whole life science cycle and we can now offer a much more diverse range of services than we have ever been able to in the past.”
 
“The knowledge that Prolytic has regarding DNA and RNA is a key scientific element of the advanced therapies services market that Kymos is entering,” said Dr. Joan Puig de Dou, CEO at Kymos. “The merger gives us the opportunity to increase our service offering, strengthen the emerging therapies market and create a multinational and multidisciplinary company. We are very much looking forward to this new phase in the company’s history.”
 
With this merger, Kymos now has three sites in Europe: in Barcelona (Spain), Ancona (Italy) and Frankfurt (Germany). The Italian site is the result of the 2016 merger with Pharmaprogress SRL. Under the agreement, the company names will remain unchanged. At Prolytic's German site, the current management will remain in place, while staff numbers and investment equipment are expected to increase.
The European group also aims to expand into the Asia-Pacific region, whilst opening up promising new therapeutic areas.


Digital Edition

International Labmate March 2021

March 2021

In This Edition Articles - dia-PASEF: A Result of the Co-evolution of Mass Spectrometry and Proteomics - Soft-Condensed Matter Science has a bright future via the Diamond-II upgrade Chrom...

View all digital editions

Events

PITTCON 2021

Mar 08 2021 Virtual Event

Bio-Europe Spring

Mar 22 2021 Digital event

Medtec Japan 2021

Apr 14 2021 Tokyo, Japan

MedtecLIVE

Apr 20 2021 Virtual event

ChemBio Finland - Virtual preview

Apr 28 2021 Virtual event

View all events